Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Sorry I sold some today to get my initial investment back :(. I still have a core position riding free from $1.40 though and I'll be looking to add if it dips even more
Do we get DDD shares since they are.buying cimt out?
http://www.gppfunds.com/team/Bernhard_Hampl.html
Bernhard Hampl, Ph.D.
Board Member
Email: Dr. Bernhard Hampl
Dr. Hampl joined Great Point Partners' Advisory Board in 2011 and is Co-Chairman of the Board of Directors our portfolio company Cytovance Biologics. He is also currently on the Board of Chenwerth Inc., a leading Active Pharmaceutical Ingredient ("API") provider to the pharmaceutical industry and a Board Member of UConn Ventures. Previously, Dr. Hampl was Executive Chairman of the Board of APP / Fresenius Kabi U.S. from 2009 to 2012.
Prior to that, Dr. Hampl was CEO of Eon Labs from 1996 to 2005 until the acquisition by Novartis at which time he became the CEO of the Sandoz US-division of Novartis. During the period he was CEO of Eon, its revenue grew from $20 million to $435 million.
Dr. Hampl earned a Ph.D. in Pharmaceutical Chemistry from the Ludwig Maximilian University of Munich, Germany, School of Chemistry and Pharmacy.
CEO Experience
Sandoz US-division of Novartis – biosimilar, biologic and generic pharmaceuticals
Eon Labs – specialty pharmaceuticals
Ceramics have a lot of uses. In aerospace it's used for high heat areas ie. Exhaust on jet engines. Space shuttles. Repair times on ceramics are long and the procedures are time consuming/delicate ie. On f 22 raptors and b2 bombers.
The CTO is for the Form 8K/A filed on Mar 30, 2012
10.26 3D Bio-Printer Development Program Agreement, dated as of March 3, 2011, by and between Invetech Pty Ltd (“Invetech”) and Organovo Holdings, Inc.*, ****
http://www.sec.gov/Archives/edgar/data/1497253/999999999714010984/filename1.pdf
http://www.sec.gov/Archives/edgar/data/1497253/000119312512143949/filename1.htm
http://www.sec.gov/Archives/edgar/data/1497253/000119312512143940/d324232d8ka.htm
I believe this will answer your question.
Definition of 'Non-Operating Asset'
Classes of assets that are not essential to the ongoing operations of a business, but may still generate income or provide a return on investment. These assets will be listed on the balance sheet along with operating assets, and may or may not be broken out separately.
Non-operating assets are held by companies for several reasons. It could be an asset related to a closed portion of the business, and might be sold in the future. Non-operating assets can also be used to diversify operational risks (for example by owning some real estate or patents) or simply used as a cash investment.
Also known as "redundant assets".
http://www.investopedia.com/terms/n/nonoperatingasset.asp
During the three months ended March 30, 2014, the Company also sold 50,000 shares of MediSwipe common stock it owned and has realized proceeds of approximately $16,554 from the sales.
http://www.sec.gov/cgi-bin/viewer?action=view&cik=1558465&accession_number=0001264931-14-000269&xbrl_type=v#
If 800com ever trades i'm guessing ~0.33/share?
sucks.. but good buying opportunity again...
been looking at CTIX for a couple weeks, does ctix plan on uplisting anytime soon?
their pipeline looks interesting, lot of risk/reward from what I'm reading especially being pink and no income...
put the company name in the sponsor section in the advanced search criteria
The C Diff Foundation welcomes Brian Andresen; Chairperson of the Biologic R & D Development Committee
http://cdifffoundation.org/2014/02/13/the-c-diff-foundation-welcomes-brian-andresen-chairperson-of-the-biologic-r-d-development-committee/
April is going to be a good month!
ORDER GRANTING CONFIDENTIAL TREATMENT
http://www.sec.gov/Archives/edgar/data/894158/999999999713017791/filename1.pdf
CBS Dallas / Fort Worth featured Organovo: 3-D Printer Creates Organ Tissue
http://dfw.cbslocal.com/2014/02/06/3-d-printer-creates-organ-tissue/?utm_content=bufferf2217&utm_medium=social&utm_source=twitter.com&utm_campaign=buffer
www.mediswipe.com
Yea, i'll probably check back on this stock in a couple months. Holding some shares... not worried if I lose it all though.
http://www.researchandmarkets.com/reports/2531222/bioabsorbable_stents_global_strategic_business#relb0
BIOABSORBABLE STENTS
A GLOBAL STRATEGIC BUSINESS REPORT
CONTENTS
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-2
Quantitative Techniques & Analytics I-2
Product Definitions and Scope of Study I-3
II. Executive Summary
1. INDUSTRY OVERVIEW II-1
A Prelude II-1
Evolution of Coronory Stents II-1
Current Global Coronory Stent Scenario - A Few Key Facts II-2
Bioabsorbable Stents Poised to Replace Drug-Eluting Stents in
Future II-2
Market Overview II-3
Current & Future Analysis II-3
Growth Drivers II-4
Restenosis - the Real Growth Driver II-4
Aging Population Propels Coronary Stents Market II-4
Limitations and Challenges Ahead II-4
Technological Challenges II-5
Safety- Efficacy Factor II-5
Regulatory Challenges II-5
Price Factor II-5
Threats to Coronary Stents - Alternative Therapies/Devices II-5
Cell Transplantation - A Threat to Coronary Stents II-6
Regulations for Conducting Clinical Trials Bioabsorbable
Stents in Select Regions II-6
The United States II-6
Europe II-6
Australia II-7
Competitive Scenario II-7
Focus on Select Bioabsorbable Stents II-7
Absorb® (Abbott Laboratories, US) II-7
ART Bioabsorbable Stent (Arterial Remodeling Technologies,
France) II-8
DREAMS (BIOTRONIK, Germany) II-8
DESolve™ Coronary Scaffold (Elixir Medical, US) II-8
IGAKI-TAMAI® (Kyoto Medical Planning, Japan) II-8
ReZolve® (REVA Medical Inc., US) II-9
2. PRODUCT OVERVIEW II-10
Coronary Artery Disease-A Perspective II-10
Treatment Options for Coronary Artery Disease II-10
Percutaneous Coronary Intervention (PCI) II-10
Coronary Stenting II-10
Types of Coronary Stents II-11
Bare Metal Stents (BMS) II-11
Drug Eluting Stents (DES) II-11
Bioabsorbable Stents II-12
Design and Composition of Bioabsorbable stents II-12
Different Types of Bioabsorbable Stents II-12
Metallic Bioabsorbable Stents II-12
Polymer Bioabsorbable Stents II-13
Degradation Period of Select Bioabsorbable Materials II-13
Advantages of Bioabsorbable stents II-13
Challenges II-14
Other Treatment Options for Coronary Heart Disease II-15
Coronary Artery Bypass Grafting (CABG) II-15
Minimally Invasive Direct Coronary Artery Bypass (MIDCAB) II-15
TransMyocardial Laser Revascularization (TMR) II-15
Peripheral Arterial Disease: Understanding the Stealthy Peril II-15
Treatment for PAD II-16
Lifestyle Changes II-16
Medication II-16
Surgery II-17
Stenting- A Treatment Option for PAD II-17
Definition of Key Endpoints Used for Assessing Efficiency of
Stents II-18
MACE (Major Adverse Cardiac Events) II-18
Restenosis II-18
Stent Thrombosis II-18
Target Lesion Revascularization (TLR) II-19
3. PRODUCT LAUNCH/INTRODUCTION II-20
Abbott Laboratories Launches Absorb™ BVS in Europe and Other
Select Geographies II-20
4. RECENT INDUSTRY ACTIVITY II-21
Abbott Laboratories Initiates ABSORB III Clinical Trial in the US II-21
ART Conducts First-in-Human Implant of ART Bioabsorbable Stent II-21
Kyoto Medical Planning Releases Data to Demonstrate Efficacy
of IGAKI-TAMAI® Stent II-21
REVA Medical Receives Clearance to Conduct Clinical Trials for
ReZolve® in Brazil and Germany II-22
Xenogenics Acquires Ideal™ BioStent Assets from Investment Funds II-22
ART Discloses Data for ART Bioabsorbable Stent Platform II-23
5. FOCUS ON SELECT GLOBAL PLAYERS II-24
Abbott Laboratories (US) II-24
Amaranth Medical, Inc. (US) II-24
Arterial Remodeling Technologies SA (France) II-25
BIOTRONIK SE & Co. KG (Germany) II-25
Elixir Medical Corporation (US) II-25
Kyoto Medical Planning Co., Ltd. (Japan) II-26
REVA Medical, Inc. (US) II-26
6. GLOBAL MARKET PERSPECTIVE II-27
Table 1: World Current and Future Analysis for Bioabsorbable
Stents by Geographic Region - US, Europe, Asia-Pacific, and
Rest of World Markets Independently Analyzed with Annual Sales
in ‘000 Units for Years 2013 through 2018 (includes
corresponding Graph/Chart) II-27
Table 2: World 6-Year Perspective for Bioabsorbable Stents by
Geographic Region - Percentage Breakdown of Volume Sales for
US, Europe, Asia-Pacific, and Rest of World Markets for Years
2013 and 2018 (includes corresponding Graph/Chart) II-28
III. MARKET
1. THE UNITED STATES III-1
A.Market Analysis III-1
Market Overview III-1
Growth III-1
Coronary Artery Disease - A US Perspective III-1
Baby Boomers Boost Coronary Stent Market III-1
Challenges Ahead III-2
Current and Future Analysis III-2
Products in the Pipeline III-2
Competitive Scenario III-2
Strategic Corporate Developments III-2
Key Players III-3
B.Market Analytics III-5
Table 3: The US Current and Future Analysis for
Bioabsorbable Stents with Annual Sales in ‘000 Units for
Years 2013 through 2018 (includes corresponding Graph/Chart) III-5
2. EUROPE III-6
A.Market Analysis III-6
Overview III-6
Growth Drivers III-6
Cardiovascular Disease in Europe - A Perspective III-6
Highly Diverse Europe III-6
Product Launch III-7
Strategic Corporate Developments III-7
Key Players III-9
B.Market Analytics III-10
Table 4: European Current and Future Analysis for
Bioabsorbable Stents with Annual Sales in ‘000 Units for
Years 2013 through 2018 (includes corresponding Graph/Chart) III-10
3. ASIA-PACIFIC III-11
A.Market Analysis III-11
Overview III-11
A Few Key Facts III-11
Asia-Pacific - A Price Sensitive Market III-11
Growth drivers III-11
Current and Future Analysis III-12
A Regional Perspective III-12
Japan III-12
Prospects Weighed down by Regulatory Entanglements III-12
Japanese Coronary Stents Command Higher Prices III-12
Competitive Landscape III-12
China III-13
Healthcare Reforms to Propel Stent Market III-13
Strategic Corporate Development III-13
Kyoto Medical Planning Co., Ltd. - A Key Player III-13
B.Market Analytics III-14
Table 5: Asia-Pacific Current and Future Analysis for
Bioabsorbable Stents with Annual Sales in ‘000 Units for
Years 2013 through 2018 (includes corresponding Graph/Chart) III-14
4. REST OF WORLD III-15
Market Analysis III-15
Table 6: Rest of World Current and Future Analysis for
Bioabsorbable Stents with Annual Sales in ‘000 Units for
Years 2013 through 2018 (includes corresponding Graph/Chart) III-15
IV. COMPETITIVE LANDSCAPE
Total Companies Profiled: 16 (including Divisions/Subsidiaries - 17)
The United States (9)
Japan (1)
Europe (4)
- France (1)
- Germany (2)
- The United Kingdom (1)
Asia-Pacific (Excluding Japan) (3)
going to test the 52 wk high 2.10
good news
wishful thinking... lol
i've been holding for over a year. i missed the last run up to sell, holding for some more positive news
I should have waited to load. Should have known they were going to raise funds since they have no real revenue. Still looking forward to next year though. Ill hold it.
Good stuff!
Added some. Lets see some good news!!
Whole sector is down
Avging down but stock keeps going lower. Time to buy more!
:( what broker do you use?
Whats going on here...
3.25k @ $.065
do you think it will rebound tomorrow or continue to fall below 5
would like to pick up more around 4 as well. will wait
I currently own 530 @ ~$4.6. I want to buy more but I don't know how I feel about averaging up